Estimation of the Placental Volume by 3D Ultrasound at 12, 16 and 22 Weeks : Relation With Growth Factors and D-Dimers

Study Overview
=================
Brief Summary
-----------------
Pregnancy complications called PVP are mainly responsible for perinatal mortality. In these cases, the placenta is smaller and often the centre of thrombotic lesions. The estimation of the placenta volume by 3D ultrasound coupled with growth factors and D-Dimers measures could improve the understanding of these pathologies to optimize their detection.

Detailed Description
-----------------
Pregnancy complications called Placental Vascular Pathologies (PVP) are mainly responsible for perinatal mortality. In these cases, the placenta is smaller and often the centre of thrombotic lesions. The estimation of the placenta volume by 3D ultrasound coupled with growth factors and D-Dimers measures could improve the understanding of these pathologies to optimize their detection. Thus, the identification of predictive factors of the risk of occurrence or recurrence of PVP could allow us to propose a monitoring of patients at risk, to anticipate corticoids administration for the foetuses pulmonary maturation and perhaps later to adapt anti hypertensive and antithrombotic therapeutics.

Official Title
-----------------
Estimation of the Placental Volume by 3D Ultrasound at 12, 16 and 22 Weeks : Relation With Growth Factors and D-Dimers - Monocentric Prospective Cohort

Conditions
-----------------
Placenta Vascular Malformation

Intervention / Treatment
-----------------
* Other: blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: previous history of one or more PVC episodes : preeclampsia, HELLPs, retroplacental hematoma, vascular IUGR<10th percentile, recurrence miscarriage >2, unexplained IUFD or IUFD after abruption placentae, eclampsia. coming for a 12 weeks ultrasound Exclusion Criteria: Multiple pregnancy past history of in utero fetal death due to congenital malformations, rhesus incompatibility or an infection previous history of IUGR which etiology was a chromosomal, genic or infectious anomaly

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pregnant patients with VPP antecedent<br>Pregnancy women consulting for an scan during their 12th week of amenorrhea at the University Hospital of Saint Etienne will be studied in this clinical trial. They have an history of VPP (Vascular Placental Pathology). They will have to give a blood sample. | Other: blood sample<br>* biological markers evaluated : D-Dimer, sEPCR<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| placental volume by 3D ultrasound and D-Dimers rate |  | Week 12 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| EPCRs rate measurements |  | Week 12 | 
| EPCRs rate measurements |  | Week 16 | 
| EPCRs rate measurements |  | Week 22 | 
| Occurrence or recurrence of PVP |  | Week 12 | 
| Occurrence or recurrence of PVP |  | Week 16 | 
| Occurrence or recurrence of PVP |  | Week 22 | 
| placental volume by 3D ultrasound and D-Dimers rate |  | Week 16 | 
| placental volume by 3D ultrasound and D-Dimers rate |  | Week 22 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
preeclampsia, eclampsia, retroplacental hematoma, vascular IUGR, IUFD, placental volume